After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it ...

Hetero Labs could launch its generic sleep disorder drug as early as 2040 under a settlement deal with Axsome Therapeutics.

Indy biotech Syndeio launches with $90M, led by CEO Derek Small, to develop NMDA receptor drugs for depression & Alzheimer's, ...

Devoted Health, the Medicare Advantage insurer with a medical group, has laid off about 120 employees. The layoffs, which ...

Angelini will pay $50 million upfront and up to $520 million in biobucks to Grin for the ex-North America rights to ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...